尿路上皮がん

Enfortumab vedotin (EV) therapy in advanced urothelial carcinoma is frequently associated with cutaneous adverse events (cAEs). These EV-induced skin toxicities correlate independently with improved progression-free and overall survival, even after adjusting for confounders like immune checkpoint inhibitor use.